Nikhat IMAM, Aftab ALAM, Mohd Faizan SIDDIQUI, Md. Mushtaque, Rafat ALI, Romana ISHRAT

Covid-19: current knowledge, disease potential, prevention and clinical advances

The top priority of any nation is to lead the nation towards prosperity, progress, and economic growth, confronting several challenges and concerns arisen from global situations. The sudden outbreak of any disease defies the health care systems and economy of nations. COVID-19 is one of the viral diseases which broke out in Wuhan city of China in 2019. COVID-19 outbreak intermittently prevailed all over the world. It exposes the fragility of the established health care systems across the world in spite of comprising modern science and technology. Unfortunately, there is no chemotherapeutic agent in the regimen of antiviral drugs or no vaccine available to curb this infectious disease. As a consequence, this deadly infection has prevailed all over the world. The antiviral drugs used for viral diseases excluding COVID-19 infection are Ramdesvir, Favipiravir, and Ribavarin, and antimalarial agents (Chloroquine & Hydroxychloroquine) are being administered to the patients for redemption of this infection. Fortunately, these existing drugs have been found clinically active and are being used. In this review, we present the current scenario and status of epidemiology, diagnosis, treatment, vaccine development for COVID-19, and its impact on the socio-economic structure.

PDF

___

Alam A, Imam N, Farooqui A, Ali S, Malik Md Z et al. (2017). Recent trends in ZikV research: A step away from cure. Biomedicine & Pharmacotherapy 91: 1152-1159. doi: 10.1016/j. biopha.2017.05.045
Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S et al. (2018). Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19. Article no: 81. doi: 10.1186/s13063-017-2427-0
Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A et al. (2014). Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrobial Agents and Chemotherapy 58: 120-127. doi: 10.1128/AAC.01407-13
Chhikara BS, Rathi B, Singh J, Poonam (2020). Corona virus SARSCoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. Chemical Biology Letters 7 (1): 63-72.
Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY et al. (2015). Middle East Respiratory Syndrome Coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews 28: 465-522. doi: 10.1128/CMR.00102- 14
Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H et al. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 395: 514-523. doi: 10.1016/ S0140-6736(20)30154-9
Chen N, Zhou M, Dong X, Qu J, Gong F et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395: 507-513. doi: 10.1016/S0140-6736(20)30211-7
Cheng K-W, Cheng S-C, Chen W-Y, Lin M-H, Chuang S-J et al. (2015). Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Research 115: 9-16. doi: 10.1016/j.antiviral.2014.12.011
Cheng VCC, Lau SKP, Woo PCY, Yuen KY (2007). Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiology Reviews 20: 660- 694. doi: 10.1128/CMR.00023-07
Cohen FS (2016). How viruses invade cells. Biophysical Journal 110: 1028-1032. doi: 10.1016/j.bpj.2016.02.006
Cohen J (2020). Wuhan seafood market may not be source of novel virus spreading globally. Science. doi: 10.1126/science.abb0611
Cyranoski D (2020). Did pangolins spread the China coronavirus to people? Nature. doi: 10.1038/d41586-020-00364-2
de Clercq E (2019). New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chemistry – An Asian Journal 14: 3962-3968. doi: 10.1002/asia.201900841
de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ (2017a). Host factors in coronavirus replication. In: Tripp RA, Tompkins SM (editors). Roles of Host Gene and Non-Coding RNA Expression in Virus Infection. Springer, Cham. pp. 1-42. doi: 10.1007/82_2017_25
de Wilde AH, Falzarano D, Zevenhoven-Dobbe JC, Beugeling C et al. (2017b). Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Research 228: 7-13. doi: 10.1016/j. virusres.2016.11.011
de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016). SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology 14: 523-534. doi: 10.1038/ nrmicro.2016.81
Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA (2015). Inhibitors of the Hepatitis C virus polymerase; mode of action and resistance. Viruses 7: 5206-5224. doi: 10.3390/v7102868
Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A et al. (2013). Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nature Medicine 19: 1313-1317. doi: 10.1038/nm.3362
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C (2020). Severe acute respiratory syndrome-related coronavirus : The species and its viruses – a statement of the Coronavirus Study Group. bioRXiv. doi: 10.1101/2020.02.07.937862
Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J (2014). Interferon- and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. Journal of General Virology 95: 571-577. doi: 10.1099/ vir.0.061911-0
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J (2020). First case of 2019 novel coronavirus in the United States. The New England Journal of Medicine 382: 929-936. doi: 10.1056/ NEJMoa2001191
Huang C, Wang Y, Li X, Ren L, Zhao J et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395: 497-506. doi: 10.1016/S0140- 6736(20)30183-5
Ito K, Yotsuyanagi H, Sugiyama M, Yatsuhashi H, Karino Y (2016). Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan: Genotype A HBV in Japanese AHB and CHB. Journal of Gastroenterology and Hepatology 31: 180- 189. doi: 10.1111/jgh.13030
Ji W, Wang W, Zhao X, Zai J, Li X (2020). Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross‐species transmission from snake to human. Journal of Medical Virology 92 (4): 433-440. doi: 10.1002/jmv.25682
Ju J, Li X, Kumar S, Jockusch S, Chien M et al. (2020). Nucleotide analogues as inhibitors of SARS-CoV polymerase. bioRXiv. doi: 10.1101/2020.03.12.989186
Kim UJ, Won E-J, Kee S-J, Jung S-I, Jang H-C (2015). Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report. Antiviral Therapy 21: 455-459. doi: 10.3851/IMP3002
Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR (2015). Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East Respiratory Syndrome Coronavirus infection as identified by temporal kinome analysis. Antimicrobial Agents and Chemotherapy 59: 1088- 1099. doi: 10.1128/AAC.03659-14
Li G, De Clercq E (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 19: 149-150. doi: 10.1038/d41573-020-00016-0
Li H, Mendelsohn E, Zong C, Zhang W, Hagan E (2019). Humananimal interactions and bat coronavirus spillover potential among rural residents in Southern China. Biosafety and Health 1: 84-90. doi: 10.1016/j.bsheal.2019.10.004
Liu W, Morse JS, Lalonde T, Xu S (2020). Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV. ChemBioChem 21: 730-738. doi: 10.1002/cbic.202000047
Lu R, Zhao X, Li J, Niu P, Yang B et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395 (10224): 565-574. doi: 10.1016/S0140-6736(20)30251-8
Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW et al. (2020). Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRXiv. doi: 10.1101/2020.04.16.20065920
Müller C, Schulte FW, Lange-Grünweller K, Obermann W, Madhugiri R et al. (2018). Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Research 150: 123-129. doi: 10.1016/j. antiviral.2017.12.010
Oberg B (2006). Rational design of polymerase inhibitors as antiviral drugs. Antiviral Research 71: 90-95. doi: 10.1016/j. antiviral.2006.05.012
O’Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PKS et al. (2010). Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae. Journal of Virology. 84: 2511-2521. doi: 10.1128/JVI.02322-09
Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA et al. (2011). The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathogens 7 (19): e1002331. doi: 10.1371/journal.ppat.1002331
Rossignol J-F (2014). Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Research 110: 94-103. doi: 10.1016/j. antiviral.2014.07.014
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J et al. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications 11: 222. doi: 10.1038/ s41467-019-13940-6
Wang M, Cao R, Zhang L, Yang X, Liu J et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 30: 269-271. doi: 10.1038/s41422-020-0282-0
Wang N, Li S-Y, Yang X-L, Huang H-M, Zhang Y-J et al. (2018). Serological evidence of bat SARS-related coronavirus infection in humans, China. Virologica Sinica 33: 104-107. doi: 10.1007/ s12250-018-0012-7
Wang W, Tang J, Wei F (2020). Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. Journal of Medical Virology 92 (4): 441-447. doi: 10.1002/jmv.25689
Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL et al. (2014). Protection against filovirus diseases by a novel broadspectrum nucleoside analogue BCX4430. Nature 508, 402-405. doi: 10.1038/nature13027
Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R et al. (2015). Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research 116: 76-84. doi: 10.1016/j.antiviral.2015.01.011
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y (2016). Coronaviruses — drug discovery and therapeutic options. Nature Reviews Drug Discovery 15: 327-347. doi: 10.1038/ nrd.2015.37